Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 27

1.

Design and Preclinical Development of TransCon PTH, an Investigational Sustained-Release PTH Replacement Therapy for Hypoparathyroidism.

Holten-Andersen L, Pihl S, Rasmussen CE, Zettler J, Maitro G, Baron J, Heinig S, Hoffmann E, Wegge T, Krusch M, Faltinger F, Killian S, Sprogoe K, Karpf DB, Breinholt VM, Cleemann F.

J Bone Miner Res. 2019 Jul 10. doi: 10.1002/jbmr.3824. [Epub ahead of print]

PMID:
31291476
2.

TransCon CNP, a sustained-release C-Type Natriuretic Peptide prodrug, a potentially safe and efficacious new therapeutic modality for the treatment of comorbidities associated with FGFR3-related skeletal dysplasias.

Breinholt VM, Rasmussen CE, Mygind PH, Kjelgaard-Hansen M, Faltinger F, Bernhard A, Zettler J, Hersel U.

J Pharmacol Exp Ther. 2019 Jun 24. pii: jpet.119.258251. doi: 10.1124/jpet.119.258251. [Epub ahead of print]

3.

Judging social interaction in the Heider and Simmel movie.

Rasmussen CE, Jiang YV.

Q J Exp Psychol (Hove). 2019 Sep;72(9):2350-2361. doi: 10.1177/1747021819838764. Epub 2019 Mar 28.

PMID:
30827187
4.

Long-Term Safety of PEGylated Coagulation Factor VIII in the Immune-Deficient Rowett Nude Rat.

Rasmussen CE, Nowak J, Larsen JM, Moore E, Bell D, Liu KC, Sorensen NS, Kappers WA, Krogh-Meibom T, Offenberg H.

J Toxicol. 2017;2017:8496246. doi: 10.1155/2017/8496246. Epub 2017 Mar 28.

5.

Evaluation of Nonacog Beta Pegol Long-term Safety in the Immune-deficient Rowett Nude Rat (Crl:NIH-Foxn1rnu).

Rasmussen CE, Nowak J, Larsen JM, Bottomley A, Rowles A, Offenberg H.

Toxicol Pathol. 2016 Jul;44(5):726-37. doi: 10.1177/0192623316633311. Epub 2016 Mar 2.

PMID:
26940713
6.

Gaussian Processes for Data-Efficient Learning in Robotics and Control.

Deisenroth MP, Fox D, Rasmussen CE.

IEEE Trans Pattern Anal Mach Intell. 2015 Feb;37(2):408-23. doi: 10.1109/TPAMI.2013.218.

7.

Alpha-smooth muscle actin and serotonin receptors 2A and 2B in dogs with myxomatous mitral valve disease.

Cremer SE, Moesgaard SG, Rasmussen CE, Zois NE, Falk T, Reimann MJ, Cirera S, Aupperle H, Oyama MA, Olsen LH.

Res Vet Sci. 2015 Jun;100:197-206. doi: 10.1016/j.rvsc.2015.03.020. Epub 2015 Mar 19.

PMID:
25843893
8.

Matrix metalloproteinases (MMPs), tissue inhibitors of metalloproteinases (TIMPs) and transforming growth factor-β (TGF-β) in advanced canine myxomatous mitral valve disease.

Moesgaard SG, Aupperle H, Rajamäki MM, Falk T, Rasmussen CE, Zois NE, Olsen LH.

Res Vet Sci. 2014 Dec;97(3):560-7. doi: 10.1016/j.rvsc.2014.10.003. Epub 2014 Oct 13.

PMID:
25458505
9.

Holter monitoring of small breed dogs with advanced myxomatous mitral valve disease with and without a history of syncope.

Rasmussen CE, Falk T, Domanjko Petrič A, Schaldemose M, Zois NE, Moesgaard SG, Ablad B, Nilsen HY, Ljungvall I, Höglund K, Häggström J, Pedersen HD, Bland JM, Olsen LH.

J Vet Intern Med. 2014 Mar-Apr;28(2):363-70. doi: 10.1111/jvim.12290. Epub 2014 Jan 13.

10.

Left ventricular twist and circumferential strain in dogs with myxomatous mitral valve disease.

Zois NE, Olsen NT, Moesgaard SG, Rasmussen CE, Falk T, Häggström J, Pedersen HD, Møller JE, Olsen LH.

J Vet Intern Med. 2013 Jul-Aug;27(4):875-83. doi: 10.1111/jvim.12114. Epub 2013 Jun 3.

11.

Radial and longitudinal strain and strain rate assessed by speckle-tracking echocardiography in dogs with myxomatous mitral valve disease.

Zois NE, Tidholm A, Nägga KM, Moesgaard SG, Rasmussen CE, Falk T, Häggström J, Pedersen HD, Åblad B, Nilsen HY, Olsen LH.

J Vet Intern Med. 2012 Nov-Dec;26(6):1309-19. doi: 10.1111/j.1939-1676.2012.01017.x. Epub 2012 Nov 1.

12.

Advanced electrocardiographic parameters change with severity of mitral regurgitation in Cavalier King Charles Spaniels in sinus rhythm.

Spiljak Pakkanen M, Domanjko Petrič A, Olsen LH, Stepančič A, Schlegel TT, Falk T, Rasmussen CE, Starc V.

J Vet Intern Med. 2012 Jan-Feb;26(1):93-100. doi: 10.1111/j.1939-1676.2011.00845.x. Epub 2011 Dec 14.

13.

Flow-mediated vasodilation measurements in Cavalier King Charles Spaniels with increasing severity of myxomatous mitral valve disease.

Moesgaard SG, Klostergaard C, Zois NE, Teerlink T, Molin M, Falk T, Rasmussen CE, Luis Fuentes V, Jones ID, Olsen LH.

J Vet Intern Med. 2012 Jan-Feb;26(1):61-8. doi: 10.1111/j.1939-1676.2011.00846.x. Epub 2011 Dec 13.

14.

Heart rate, heart rate variability, and arrhythmias in dogs with myxomatous mitral valve disease.

Rasmussen CE, Falk T, Zois NE, Moesgaard SG, Häggström J, Pedersen HD, Ablad B, Nilsen HY, Olsen LH.

J Vet Intern Med. 2012 Jan-Feb;26(1):76-84. doi: 10.1111/j.1939-1676.2011.00842.x. Epub 2011 Dec 13.

15.

Circulating cytokine concentrations in dogs with different degrees of myxomatous mitral valve disease.

Zois NE, Moesgaard SG, Kjelgaard-Hansen M, Rasmussen CE, Falk T, Fossing C, Häggström J, Pedersen HD, Olsen LH.

Vet J. 2012 Apr;192(1):106-11. doi: 10.1016/j.tvjl.2011.05.009. Epub 2011 Jun 21.

PMID:
21696985
16.

Holter monitoring in clinically healthy Cavalier King Charles Spaniels, Wire-haired Dachshunds, and Cairn Terriers.

Rasmussen CE, Vesterholm S, Ludvigsen TP, Häggström J, Pedersen HD, Moesgaard SG, Olsen LH.

J Vet Intern Med. 2011 May-Jun;25(3):460-8. doi: 10.1111/j.1939-1676.2011.0707.x. Epub 2011 Mar 21.

17.

Brain-natriuretic peptide and cyclic guanosine monophosphate as biomarkers of myxomatous mitral valve disease in dogs.

Moesgaard SG, Falk T, Teerlink T, Guðmundsdóttir HH, Sigurðardóttir S, Rasmussen CE, Olsen LH.

Vet J. 2011 Sep;189(3):349-52. doi: 10.1016/j.tvjl.2010.07.019. Epub 2010 Sep 6.

PMID:
20822939
18.

Modeling and visualizing uncertainty in gene expression clusters using dirichlet process mixtures.

Rasmussen CE, de la Cruz BJ, Ghahramani Z, Wild DL.

IEEE/ACM Trans Comput Biol Bioinform. 2009 Oct-Dec;6(4):615-28. doi: 10.1109/TCBB.2007.70269.

PMID:
19875860
19.

Evaluation of plasma and urinary levels of 6-keto-prostaglandin F1alpha as a marker for asymptomatic myxomatous mitral valve disease in dogs.

Rasmussen CE, Sundqvist AV, Kjempff CT, Tarnow I, Kjelgaard-Hansen M, Kamstrup TS, Sterup AL, Soerensen TM, Olsen LH.

Vet J. 2010 May;184(2):241-6. doi: 10.1016/j.tvjl.2009.02.012. Epub 2009 Mar 25.

PMID:
19324577
20.

Surface tension of quantum fluids from molecular simulations.

Zhao X, Johnson JK, Rasmussen CE.

J Chem Phys. 2004 May 8;120(18):8707-15.

PMID:
15267801
21.

Clustering protein sequence and structure space with infinite Gaussian mixture models.

Dubey A, Hwang S, Rangel C, Rasmussen CE, Ghahramani Z, Wild DL.

Pac Symp Biocomput. 2004:399-410.

22.

Perfusion quantification using Gaussian process deconvolution.

Andersen IK, Szymkowiak A, Rasmussen CE, Hanson LG, Marstrand JR, Larsson HB, Hansen LK.

Magn Reson Med. 2002 Aug;48(2):351-61.

23.

Twelve years' clinical experience with the CarboMedics prosthetic heart valve.

Aagaard J, Tingleff J, Hansen CN, Noergaard MA, Rasmussen CE.

J Heart Valve Dis. 2001 Mar;10(2):177-84.

PMID:
11297204
24.
25.

Bioinequivalence of erythromycin ethylsuccinate and enteric-coated erythromycin pellets following multiple oral doses.

Yakatan GJ, Rasmussen CE, Feis PJ, Wallen S.

J Clin Pharmacol. 1985 Jan-Feb;25(1):36-42.

PMID:
3871797
26.

Analog computer program for simulating variable dosing regimens.

Kirschner L, Simon TH, Rasmussen CE.

J Pharm Sci. 1973 Jan;62(1):117-21. No abstract available.

PMID:
4682912
27.

Spectropolarimetric and circular dichroism methods for determining the activity of penicillin.

Rasmussen CE, Higuchi T.

J Pharm Sci. 1971 Nov;60(11):1608-16. No abstract available.

PMID:
5133906

Supplemental Content

Loading ...
Support Center